Lithium for Parkinson's: an Extension Trial

PHASE1/PHASE2Enrolling by invitationINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 9, 2024

Primary Completion Date

February 1, 2026

Study Completion Date

May 1, 2026

Conditions

Parkinson Disease

Interventions

DIETARY_SUPPLEMENT

Lithium aspartate

Lithium aspartate with dosage adjusted to serum lithium level 0.25-0.50mmol/L

Trial Locations (1)

UBMD Neurology, Williamsville

All Listed Sponsors

lead

State University of New York at Buffalo

OTHER